Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Speciality Medicines
Price Band
₹117.0–124.0
Issue Size
₹29.14 Cr
Lot Size
1,000 shares
Min Investment
₹248,000
GMP
+₹0.0 (0.0%)
Issue Price
₹124.0
calendar_month Important Dates
bar_chart Subscription Status
Subscription data unavailable
trending_up Grey Market Premium (GMP)
GMP
₹0.0
GMP %
0.0%
Est. Listing
₹124.0
schedule Updated: 14 Jul 2026 15:52
Share GMP:
business About the Company
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat complex chronic conditions — across both domestic and international markets. The company’s portfolio includes a wide range of speciality pharmaceutical finished formulations such as capsules, creams, eye drops, gels, infusions, inhalations and inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, oral suspensions, sachets, suspensions, and tablets. Through wide-ranging distribution channels, the company has built a trusted reputation with clients across more than 20 states in India and over 35 countries worldwide. Speciality Medicines Limited offers over 650 products (as of July 31, 2024) under the unregistered category, with a particular focus on therapeutic areas like: Oncology Immunology Neurology Rare Diseases Additionally, the company’s product range includes human and animal medicines, vaccines, and plasma products — all sourced from manufacturers that comply with global quality standards like EUGMP and PICS. Global Expansion and Registrations As of July 31, 2024, Speciality Medicines Limited has: 1 plasma product registered in Bolivia 127 products under registration across 8 countries As of July 31, 2024, Speciality Medicines Limited employs a team of 20 permanent employees across various departments, contributing to the company’s smooth and efficient operations.
payments Company Financials (₹ Cr)
As of 2025-10-31
| Period Ended | 31 Oct 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 45.57 | 39.98 | 22.68 |
| Total Income | 36.93 | 58.54 | 27.66 |
| Profit After Tax | 6.06 | 8.61 | 2.93 |
| EBITDA | 6.51 | 9.09 | 5.26 |
| NET Worth | 36.47 | 30.42 | 15.06 |
| Reserves and Surplus | 30.04 | 23.98 | 9.95 |
| Total Borrowing | 4.81 | 5.05 | 2.86 |
Key Ratios
EPS
₹13.38
NAV
₹47.26
ROE
37.85%
ROCE
33.39%
RoNW
28.30%
P/B Value
2.62
P/E Ratio
9.27
Market Cap
₹108.94 Cr
PAT Margin
14.77%
Debt/Equity
0.17
Promoters
Parth B Goyani and Goyani Sumit Babubhai
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat 12.68 2 Product Registration in International Markets and Product Development for sale in international markets 2.99 3 Funding for Marketing and Promotional Activities 1.66 4 To Meet Working Capital Requirements 8.00 5 General Corporate Purposes 0.25 6 Issue Expenses 3.57 Total 29.14
info Issue Details
pie_chart Investor Allocation
Registrar
Lead Managers / Book Running
timeline IPO Timeline
Open
20 Mar 2026
Close
24 Mar 2026
Allotment
25 Mar 2026
Listing
30 Mar 2026